Equitable Law is pleased to announce (within the
restrictions of confidentiality to which we are subject) that we have recently
provided legal advice and assistance in relation to English Law aspects which
were relevant to the sale and purchase of an early-stage drug product.
The product has historically been developed (and is
currently owned) by an unidentified publicly traded company based in an English
speaking common law jurisdiction, and a conditional disposal has now been
agreed with another public company in a separate English speaking common law
jurisdiction.
The aggregate consideration for the transaction was a local
currency equivalent of a significant eight figure United States Dollar amount
(USD $ XX,000,000).
Considerable English law (and practical business) elements
arose in relation to the transaction, because the relevant product has historically
been developed through an English limited liability company - which (latterly)
has exploited the United Kingdom's ‘patent box legislation’ – which potentially
creates a significantly advantageous tax position for the future development and
exploitation of intellectual property which is subject to the United Kingdom’s
taxation system.
The relevant conditionally agreed sale is now awaiting
approvals from various regulatory bodies on a worldwide basis, and further
details may be announced once the specific details of this transaction becomes
publicly announced.
Friday, 20th
March 2015
For further details (within restrictions of confidentiality)
Please contact:
Dan.Johnson@EquitableLaw.com
+1 (646) 470 1880 (Worldwide Roaming e-Tel.)
